Home pageCRSP • NASDAQ
add
CRISPR Therapeutics
52,44Â $
After Hours:(0,076%)-0,040
52,40Â $
Data e ora chiusura: 31 dic, 19:46:19 GMT-5 · USD · NASDAQ · Disclaimer
Chiusura precedente
53,19Â $
Intervallo giornaliero
52,35Â $ - 53,46Â $
Intervallo annuale
30,06Â $ - 78,48Â $
Cap di mercato
5,00Â Mld USD
Volume medio
1,90Â Mln
Rapporto P/E
-
Dividendo/Prezzo
-
Borsa valori principale
NASDAQ
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
| (USD) | set 2025info | Variazione Y/Y |
|---|---|---|
Entrate | 889,00K | 47,67% |
Spese di gestione | 68,26Â Mln | -22,11% |
Utile netto | -106,44Â Mln | -23,85% |
Margine di profitto netto | -11,97K | 16,13% |
Utili per azione | -1,17 | -15,84% |
EBITDA | -127,63Â Mln | -21,10% |
Aliquota fiscale effettiva | -0,58% | — |
Stato patrimoniale
Totale attivo
Totale passivo
| (USD) | set 2025info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | 1,92Â Mld | -1,03% |
Totale attivo | 2,25Â Mld | -0,48% |
Totale passivo | 329,33Â Mln | 4,06% |
Patrimonio netto totale | 1,92 Mld | — |
Azioni in circolazione | 95,30 Mln | — |
Prezzo/valore contabile | 2,61 | — |
Redditività dell'attivo | -15,45% | — |
Rendimento sul capitale | -16,29% | — |
Flusso di cassa
Flusso di cassa netto
| (USD) | set 2025info | Variazione Y/Y |
|---|---|---|
Utile netto | -106,44Â Mln | -23,85% |
LiquiditĂ di esercizio | -84,63Â Mln | 20,84% |
Contanti da investimenti | -119,23Â Mln | 26,22% |
Contanti da finanziamenti | 296,77Â Mln | 2.978,49% |
Flusso di cassa netto | 92,88Â Mln | 135,89% |
Flusso di cassa libero | -48,16Â Mln | 40,30% |
Informazioni
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Fondazione
2013
Sito web
Dipendenti
393
